The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Strong Auvelity Sales And Alzheimer's Label Hopes [Yahoo! Finance]
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: Yahoo! Finance
and roughly US$638,500,000 for full-year 2025, with its lead therapy Auvelity outperforming earlier sales estimates. At the same time, growing attention on Auvelity's potential FDA label expansion for Alzheimer's disease agitation is reshaping how investors assess Axsome's product pipeline and future revenue mix. We'll now look at how Axsome's stronger-than-expected Auvelity performance and Alzheimer's agitation label efforts influence its broader investment narrative. Find companies with promising cash flow potential yet trading below their fair value For Axsome, the big-picture belief is that Auvelity can anchor a growing CNS portfolio long enough for late-stage assets like AXS-05 in Alzheimer's agitation, AXS-12 in narcolepsy and AXS-14 in fibromyalgia to contribute meaningfully. The interim 2025 figures, with product revenue around US$638,500,000 and Auvelity beating earlier expectations, reinforce that core thesis and help support the current premium Price-To-Sales multip
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Jefferies Financial Group Inc. from $200.00 to $245.00. They now have a "buy" rating on the stock.MarketBeat
- Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates [Yahoo! Finance]Yahoo! Finance
- Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at TD Cowen.MarketBeat
- Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Leerink Partners from $150.00 to $205.00. They now have an "outperform" rating on the stock.MarketBeat
- Top Picks 2026- Dynex Capital Inc. DX [Yahoo! Finance]Yahoo! Finance
AXSM
Earnings
- 11/3/25 - Miss
AXSM
Sec Filings
- 2/2/26 - Form 4
- 2/2/26 - Form 144
- 1/23/26 - Form 4
- AXSM's page on the SEC website